Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was e...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fiore, F, Blanchard, F, Charbonnier, F, Le Pessot, F, Lamy, A, Galais, M P, Bastit, L, Killian, A, Sesboüé, R, Tuech, J J, Queuniet, A M, Paillot, B, Sabourin, J C, Michot, F, Michel, P, Frebourg, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360149/
https://www.ncbi.nlm.nih.gov/pubmed/17375050
http://dx.doi.org/10.1038/sj.bjc.6603685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360149/
https://www.ncbi.nlm.nih.gov/pubmed/17375050
http://dx.doi.org/10.1038/sj.bjc.6603685

Ejemplares similares